Mini Review
Published on 08 Oct 2025
Anti-angiogenesis in human lymphomas. New insights
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1636332
- 518 views
Type at least 3 characters
1,939 articles
Original Research
Accepted on 07 Oct 2025
Unveiling Hypoxic Regulatory Networks by Bioinformatics: Mechanisms of Hypoxia-Related Hub Genes Driving Rituximab Resistance and Poor Prognosis in DLBCL
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1592441
- 103 views
Review
Published on 07 Oct 2025
Research advances in the adjunctive diagnosis of acute myeloid leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1634935
- 492 views
Case Report
Published on 07 Oct 2025
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1672690
- 711 views
Original Research
Accepted on 06 Oct 2025
Targeting the N-cadherin/β-catenin axis with MSAB reverses malignant phenotypes in blast crisis of CML
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1657508
Correction
Published on 06 Oct 2025
Correction: Targeting RAB7 in human B lymphoma by a small molecule inhibitor arrests tumor cell growth
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1711784
- 600 views
Case Report
Accepted on 03 Oct 2025
Hereditary spherocytosis concomitant with JAK2V617F-positive primary myelofibrosis: A case report
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1665179
- 149 views
Original Research
Published on 03 Oct 2025
Improvement of revised international staging system risk stratification in patients with newly diagnosed multiple myeloma using a high bone marrow plasma cell percentage: a real-world study in China
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1627653
- 664 views
Original Research
Published on 02 Oct 2025
Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1669385
- 1,399 views
Case Report
Published on 01 Oct 2025
Case Report: A rare RUNX1 rearrangement resulting from t(8;21)(p12;q22) in acute myeloid leukemia with plasmacytoid dendritic cell expansion
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1672416
- 488 views
Brief Research Report
Published on 01 Oct 2025
Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1656912
- 605 views
Original Research
Accepted on 30 Sep 2025
Evaluating the Effectiveness of Integrated Care in Targeted Therapy for Patients with Chronic Lymphocytic Leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1685510
- 131 views
Original Research
Accepted on 30 Sep 2025
The Prognostic Significance of Incomplete Hematological Recovery in Pediatric Patients with Low/Intermediate Risk AML and Negative MRD after Induction 1
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1661036
- 106 views
Original Research
Published on 30 Sep 2025
The significance of PET/CT combined with machine learning models for the classification of lymphoma involvement and metastases in enlarged lymph nodes
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1643924
- 479 views
Systematic Review
Accepted on 29 Sep 2025
Comparing therapeutic effects of hematopoietic stem cell transplantation, tyrosine kinase inhibitors and chemotherapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and meta-analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1627825
- 259 views
Original Research
Accepted on 29 Sep 2025
B7-H7 knockdown suppresses the proliferation, metastasis, and drug resistance of B-cell non-Hodgkin lymphoma cells by inhibiting the PI3K/Akt pathway
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1665309
- 247 views